Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer

NCT04005144 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped Low Accrual

Conditions

ALK Gene Rearrangement
Lung Non-Small Cell Carcinoma
Progressive Disease
ROS1 Gene Rearrangement
Stage IIIB Lung Cancer
Stage IIIC Lung Cancer
Stage IV Lung Cancer
Stage IVA Lung Cancer
Stage IVB Lung Cancer

Interventions

DRUG: Binimetinib
DRUG: Brigatinib

Sponsor

University of California, San Francisco

Collaborators

[object Object]
[object Object]